Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Outcomes of Patients (pts) with Myelodysplatic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) Post Clofarabine Failure

Hady Ghanem, MD, Guillermo Garcia Manero, MD, Stefan Faderl, MD, Koichi Takahashi, MD, Farhad Ravandi, Jorge E. Cortes, MD, Susan O'Brien, M.D., Naval G. Daver, MD, Lakshmikanth Katragadda, MD, Naveen Pemmaraju, M.D., Sherry A. Pierce, RN, BS, Alfonso Quintás-Cardama, MD, Tapan M. Kadia, M.D., Hagop M. Kantarjian, MD, Elias J. Jabbour, MD

Blood (2012) 120 (21): 1722.

https://doi.org/10.1182/blood.V120.21.1722.1722

Published: 2012

Journal Articles

Real-Time Quantitative Polymerase Chain Reaction (RQ-PCR) On Peripheral Blood (PB) and Bone Marrow (BM) Samples for Monitoring Minimal Residual Disease (MRD) in Patients (pts) with Acute Promyelocytic Leukemia (APL) Treated with All-Trans-Retinoic Acid (ATRA) and Arsenic Trioxide (ATO).

Hady Ghanem, MD, Hagop M. Kantarjian, MD, Stefan Faderl, MD, Elias J. Jabbour, MD, Naval Daver, MD, Sherry A. Pierce, RN, BS, Mark Brandt, BS, Alfonso Quintás-Cardama, MD, Rajyalakshmi Luthra, PhD, Guillermo Garcia-Manero, MD, Jorge E. Cortes, MD, Farhad Ravandi, MD

Blood (2012) 120 (21): 2623.

https://doi.org/10.1182/blood.V120.21.2623.2623

Published: 2012

Journal Articles

Outcome of Elderly Patients with Acute Myeloid Leukemia (AML) Post Hypomethylating Agent (HMA) Failure.

Koichi Takahashi, MD, Hagop M. Kantarjian, MD, Hady Ghanem, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Tapan M. Kadia, M.D., Susan O'Brien, M.D., Sherry A. Pierce, RN, BS, Nitin Jain, MD, Guillermo Garcia-Manero, MD, Elias J. Jabbour, MD

Blood (2012) 120 (21): 2627.

https://doi.org/10.1182/blood.V120.21.2627.2627

Published: 2012

Journal Articles

Outcome of Patients (pts) with Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure.

Elias J. Jabbour, MD, Naval G. Daver, MD, Tina (Xiao Qin) Dong, Tapan M. Kadia, M.D., Susan O'Brien, M.D., Jorge E. Cortes, MD, Farhad Ravandi, MBBS, Naveen Pemmaraju, M.D., Hady Ghanem, MD, Stefan Faderl, MD, Gautam Borthakur, M.D., Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2012) 120 (21): 2824.

https://doi.org/10.1182/blood.V120.21.2824.2824

Published: 2012

Journal Articles

Biphenotypic Blast Phase (B-BP) of Chronic Myeloid Leukemia (CML): A Single Institution Experience

Hady Ghanem, MD, Hagop M. Kantarjian, MD, Elias Jabbour, Lakshmikanth Katragadda, MD, Jorge E. Cortes, MD, Naveen Pemmaraju, M.D., Alfonso Quintás-Cardama, M.D.

Blood (2012) 120 (21): 1687.

https://doi.org/10.1182/blood.V120.21.1687.1687

Published: 2012

Journal Articles

Outcomes of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) After Surviving 5 Years of Initial Therapy with Interferon Alpha (IFN), Imatinib (IMA) or Allogeneic Stem Cell Transplantation (ASCT)

Hady Ghanem, MD, Hagop M. Kantarjian, MD, Richard E. Champlin, Lakshmikanth Katragadda, MD, Gabriela Rondon, MD, Elias J. Jabbour, MD, Alfonso Quintás-Cardama, MD, Sherry A. Pierce, RN, BS, Jorge E. Cortes, MD

Blood (2012) 120 (21): 2001.

https://doi.org/10.1182/blood.V120.21.2001.2001

Published: 2012

Journal Articles

Rare Blast Phase (BP) Phenotypes of Chronic Myeloid Leukemia (CML)

Hady Ghanem, MD, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD, Jorge E. Cortes, MD, Alfonso Quintás-Cardama, MD

Blood (2012) 120 (21): 4434.

https://doi.org/10.1182/blood.V120.21.4434.4434

Published: 2012

Journal Articles

Twice Daily Fludarabine and Cytarabine Combination (BID-FA) Is Effective in Pts with De Novo Acute Myeloid Leukemia (AML), Relapsed/Refractory (R/R) AML, High-Risk Myelodysplastic Syndromes (MDS), and Blast Phase Chronic Myeloid Leukemia (CML-BP)

Hady Ghanem, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Naveen Pemmaraju, M.D., Stefan Faderl, MD, Sara E Dellasala, RN, Susan M. O'Brien, MD, Jan A. Burger, MD, PhD, Gautam Borthakur, M.D., Tapan M. Kadia, M.D., Alfonso Quintás-Cardama, MD, Mark Brandt, BS, Sherry A. Pierce, RN, BS, Guillermo Garcia-Manero, MD, Elias J. Jabbour, MD

Blood (2012) 120 (21): 4939.

https://doi.org/10.1182/blood.V120.21.4939.4939

Published: 2012

Journal Articles

Comparative Analysis of the Value of Consolidation with Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT) Versus High-Dose Cytarabine (HDAC) Based Chemotherapy in Patients (pts) with Acute Myeloid Leukemia (AML) with Chromosome Seven Abnormalities

Elias J. Jabbour, MD, Hagop M. Kantarjian, MD, Betul Oran, MD, MS, Farhad Ravandi, MD, Hady Ghanem, MD, Issa Khouri, MD, Guillermo Garcia-Manero, MD, Michael S Mathisen, PharmD, Qaiser Bashir, MD, Rima M Saliba, PhD, Maria Khouri, Sherry A. Pierce, RN, BS, Mark Brandt, BS, Richard E. Champlin, Marcos De Lima, MD

Blood (2012) 120 (21): 2029.

https://doi.org/10.1182/blood.V120.21.2029.2029

Published: 2012

Journal Articles

Very High Rate of Leukemic Transformation and Poor Survival in Patients with Lower Risk Myelodysplastic Syndrome (MDS) Who Dynamically Acquire FLT3 Molecular Alteration (FLT3m): Study of 290 MDS Patients with Sequential Mutation Analysis

Koichi Takahashi, MD, Elias J. Jabbour, MD, Xuemei Wang, MS, Hady Ghanem, MD, Naveen Pemmaraju, M.D., Farhad Ravandi, MD, Jorge E. Cortes, MD, Stefan Faderl, MD, Tapan M. Kadia, M.D., Gautam Borthakur, M.D., William G. Wierda, MD, Ph.D., Sherry A. Pierce, RN, BS, Zeev Estrov, MD, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2012) 120 (21): 3802.

https://doi.org/10.1182/blood.V120.21.3802.3802

Published: 2012

Journal Articles

Outcome of Patients (pts) with Acute Myeloid Leukemia (AML) Evolving From Myelodysplastic Syndromes (MDS) Post Hypomethyling Agents (HMA) Failure

Hady Ghanem, MD, Hagop M. Kantarjian, MD, Guillermo Garcia Manero, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Koichi Takahashi, MD, Susan M. O'Brien, MD, Sherry A. Pierce, RN, BS, Tapan M. Kadia, M.D., Elias J. Jabbour, MD

Blood (2012) 120 (21): 3600.

https://doi.org/10.1182/blood.V120.21.3600.3600

Published: 2012

Journal Articles

Dynamics of Molecular Response in Patients (pts) with Acute Myeloid Leukemia (AML) Withy Core Binding Factor (CBF) Abnormalities Treated with High-Dose Cytarabine Regimen

Elias J. Jabbour, MD, Hagop M. Kantarjian, MD, Yin Cameron, MD, PhD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Guillermo Garcia-Manero, MD, Hady Ghanem, MD, Tapan M. Kadia, M.D., Stefan Faderl, MD, Susan O'Brien, M.D., Michael S Mathisen, PharmD, Mark Brandt, BS, Naveen Pemmaraju, M.D., Deborah A. Thomas, MD, Joyce Bass, RN, Gautam Borthakur

Blood (2012) 120 (21): 3609.

https://doi.org/10.1182/blood.V120.21.3609.3609

Published: 2012

Journal Articles

Updated Results of a Phase I/II, Randomized Study of Clofarabine Combined with Idarubicin and Cytarabine (CIA) or Fludarabine Combined with Idarubicin and Cytarabine (FIA) for the Treatment of Patients (pts) with Newly Diagnosed or Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML)

Michael S Mathisen, PharmD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Naveen Pemmaraju, M.D., Guillermo Garcia-Manero, MD, Jorge E. Cortes, MD, Susan O'Brien, M.D., Alfonso Quintas-Cardama, MD, Hady Ghanem, MD, Naval G. Daver, MD, Sherry A. Pierce, RN, BS, Cynthia Lira, RN, Stefan Faderl, MD, Elias Jabbour, MD

Blood (2012) 120 (21): 3610.

https://doi.org/10.1182/blood.V120.21.3610.3610

Published: 2012

NARROW

Outcomes of Patients (pts) with Myelodysplatic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) Post Clofarabine Failure

Real-Time Quantitative Polymerase Chain Reaction (RQ-PCR) On Peripheral Blood (PB) and Bone Marrow (BM) Samples for Monitoring Minimal Residual Disease (MRD) in Patients (pts) with Acute Promyelocytic Leukemia (APL) Treated with All-Trans-Retinoic Acid (ATRA) and Arsenic Trioxide (ATO).

Outcome of Elderly Patients with Acute Myeloid Leukemia (AML) Post Hypomethylating Agent (HMA) Failure.

Outcome of Patients (pts) with Low and Intermediate-1 Risk Myelodysplastic Syndrome (MDS) After Hypomethylating Agent (HMA) Failure.

Biphenotypic Blast Phase (B-BP) of Chronic Myeloid Leukemia (CML): A Single Institution Experience

Outcomes of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) After Surviving 5 Years of Initial Therapy with Interferon Alpha (IFN), Imatinib (IMA) or Allogeneic Stem Cell Transplantation (ASCT)

Rare Blast Phase (BP) Phenotypes of Chronic Myeloid Leukemia (CML)

Twice Daily Fludarabine and Cytarabine Combination (BID-FA) Is Effective in Pts with De Novo Acute Myeloid Leukemia (AML), Relapsed/Refractory (R/R) AML, High-Risk Myelodysplastic Syndromes (MDS), and Blast Phase Chronic Myeloid Leukemia (CML-BP)

Comparative Analysis of the Value of Consolidation with Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT) Versus High-Dose Cytarabine (HDAC) Based Chemotherapy in Patients (pts) with Acute Myeloid Leukemia (AML) with Chromosome Seven Abnormalities

Very High Rate of Leukemic Transformation and Poor Survival in Patients with Lower Risk Myelodysplastic Syndrome (MDS) Who Dynamically Acquire FLT3 Molecular Alteration (FLT3m): Study of 290 MDS Patients with Sequential Mutation Analysis

Outcome of Patients (pts) with Acute Myeloid Leukemia (AML) Evolving From Myelodysplastic Syndromes (MDS) Post Hypomethyling Agents (HMA) Failure

Dynamics of Molecular Response in Patients (pts) with Acute Myeloid Leukemia (AML) Withy Core Binding Factor (CBF) Abnormalities Treated with High-Dose Cytarabine Regimen

Updated Results of a Phase I/II, Randomized Study of Clofarabine Combined with Idarubicin and Cytarabine (CIA) or Fludarabine Combined with Idarubicin and Cytarabine (FIA) for the Treatment of Patients (pts) with Newly Diagnosed or Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only